What is the appropriate antibiotic treatment for mastoiditis?

Antibiotic Treatment for Mastoiditis

For acute mastoiditis, initiate intravenous broad-spectrum antibiotics immediately—specifically a third-generation cephalosporin such as ceftriaxone 50–100 mg/kg/day (maximum 2 g/day) or cefotaxime—as first-line therapy, with consideration of myringotomy with or without tympanostomy tube insertion. 1, 2

Initial Assessment and Immediate Management

• Hospitalize all patients with acute mastoiditis and begin IV antibiotics within the first hour of diagnosis, as this is a serious complication of acute otitis media requiring prompt aggressive treatment to prevent intracranial complications. 1, 3

• Obtain microbiological samples before starting antibiotics—including myringotomy fluid, blood cultures, and any retro-auricular abscess aspirate—because culture-positive rates are significantly higher from local samples (68–81%) than blood cultures (14%), and prior antibiotic therapy does not reliably prevent mastoiditis development. 2, 4, 5

• Perform CT temporal bone with IV contrast if the patient fails to improve after 48 hours of IV antibiotics or if clinical deterioration occurs at any point, to identify complications such as subperiosteal abscess, coalescent mastoiditis, or intracranial extension. 1

First-Line Antibiotic Regimens

Pediatric Dosing (Most Common Scenario)

• Ceftriaxone 50–100 mg/kg/day IV once daily (maximum 2 g/day) is the preferred empiric agent because Streptococcus pneumoniae accounts for approximately 38.7–51% of cases, followed by Streptococcus pyogenes (11.5–14%), Staphylococcus aureus (13%), and Haemophilus influenzae. 1, 3, 2, 5

• Cefotaxime 150–200 mg/kg/day IV divided every 6–8 hours (maximum 12 g/day) is an equally effective alternative third-generation cephalosporin. 2

• Ampicillin-sulbactam 150–200 mg/kg/day IV divided every 6 hours provides broader coverage including anaerobes and is appropriate when polymicrobial infection is suspected or when Pseudomonas aeruginosa (6.4–8% of cases) is a concern. 3, 5, 6

Adult Dosing

• Ceftriaxone 1–2 g IV once daily or ampicillin-sulbactam 1.5–3 g IV every 6 hours are appropriate first-line regimens. 6

When to Broaden Coverage

• Add vancomycin 15 mg/kg IV every 6 hours (pediatric) or 15–20 mg/kg IV every 8–12 hours (adult) when MRSA is suspected, particularly in patients with prior MRSA infection, recent hospitalization, or failure of initial beta-lactam therapy. 1

• For complicated mastoiditis with intracranial extension, use vancomycin plus one of the following: piperacillin-tazobactam 3.375–4.5 g IV every 6 hours, a carbapenem (meropenem 1 g IV every 8 hours), or ceftriaxone plus metronidazole 500 mg IV every 8 hours. 1

• For confirmed Streptococcus pyogenes infection, add clindamycin 10–13 mg/kg/dose IV every 6–8 hours (pediatric) or 600 mg IV every 8 hours (adult) to penicillin therapy to reduce toxin production. 1

Surgical Decision Algorithm

• Begin with IV antibiotics alone or antibiotics plus myringotomy for 0–48 hours, then reassess for clinical improvement (reduced fever, decreased retro-auricular swelling/erythema, improved pain). 1, 7

• If no improvement after 48 hours of appropriate IV antibiotics, or if clinical deterioration occurs at any point, perform mastoidectomy rather than continuing medical management alone, as antibiotics-only success rates are only 10–24.6% versus 87.7% for antibiotics plus minor procedures and 97% for mastoidectomy. 1, 8

• Myringotomy with tympanostomy tube insertion achieves 68% success rates when combined with antibiotics and should be considered as an initial conservative surgical step before proceeding to mastoidectomy. 1

• Perform immediate mastoidectomy without a trial of medical therapy when any of the following are present: subperiosteal abscess with bony erosion/coalescence, intracranial complications (brain abscess, subdural empyema, sigmoid sinus thrombosis), facial nerve palsy, or labyrinthitis. 1, 9, 10

Transition to Oral Therapy

• Once clinical improvement is noted—typically after 4–7 days of IV therapy—transition to high-dose oral amoxicillin-clavulanate 80–90 mg/kg/day of the amoxicillin component divided twice daily (maximum 4000 mg/day) for children or 2000 mg twice daily for adults. 1

• For patients with non-immediate beta-lactam hypersensitivity, use cefdinir, cefpodoxime proxetil, or cefuroxime axetil as alternative oral cephalosporins. 1

• For patients with immediate Type I hypersensitivity to beta-lactams, use clindamycin 10–13 mg/kg/dose every 6–8 hours (pediatric) or 300–450 mg every 6 hours (adult) plus an agent covering H. influenzae and M. catarrhalis such as cefixime or cefdinir. 1

• Avoid macrolides (azithromycin, clarithromycin) due to high failure rates (20–25%) from pneumococcal resistance. 1

Treatment Duration

• Continue IV antibiotics for a minimum of 4–7 days until clear clinical improvement, then transition to oral therapy for a total antibiotic course of 10–14 days. 7, 8

• Reassess patients within 48–72 hours of switching to oral therapy to ensure continued improvement. 1

Monitoring for Complications

• Obtain MRI without and with IV contrast if intracranial complications are suspected—including brain abscess, subdural empyema, meningitis, or dural venous sinus thrombosis—as MRI has higher sensitivity and specificity than CT for these conditions. 1

• Monitor for sigmoid sinus thrombosis (3.2% incidence), seizures, meningismus, neck rigidity, and neurological deficits, as no reliable clinical signs distinguish patients with coexistent intracranial complications. 1, 3, 9

• Consider anticoagulation for sigmoid sinus thrombosis, though evidence is limited; all patients with this complication should receive IV antibiotics and grommet insertion, with cortical mastoidectomy not routinely required. 1, 9

Common Pitfalls to Avoid

• Do not delay antibiotics to obtain imaging when clinical presentation is straightforward; begin IV ceftriaxone or ampicillin-sulbactam immediately and obtain CT only if the patient fails to improve or deteriorates. 1

• Do not continue ineffective antibiotics beyond 48 hours; progression despite appropriate therapy indicates either resistant organisms or complications requiring surgical intervention. 1, 8

• Do not assume prior antibiotic treatment prevents mastoiditis; 33–81% of patients diagnosed with acute mastoiditis had received antibiotics before admission, and 54.3% were on oral antibiotics at the time of diagnosis. 1, 5

• Do not perform simple drainage of subperiosteal abscess without mastoidectomy, as surgical failures requiring more than one procedure are significantly more frequent (p≤0.001) when drainage is performed without mastoidectomy. 2

• Do not use trimethoprim-sulfamethoxazole or macrolides as step-down therapy due to substantial pneumococcal resistance. 1

Follow-Up Care

• Perform hearing assessment if middle ear effusion persists for ≥3 months, as persistent effusion is common (60–70% at 2 weeks, 10–25% at 3 months) and does not require antibiotic continuation unless symptomatic. 1

• Recurrences requiring second hospitalization occur in 4.3% of cases, more frequently with Streptococcus pneumoniae infections. 2